Latest news with #BEACON
Politico
4 days ago
- Climate
- Politico
Kevin Guthrie's 3 hurricane prep tips
Good morning and welcome to June: the start of hurricane season. There's only one Gov. RON DESANTIS. But artificial intelligence can help him be in more than two places at once — at least when it comes to emergency management. Heading into this hurricane season, Florida is using a new system called BEACON, or Broadcast Emergency Alerts and Communication Operations Network. It uses AI to comb through press releases, text messages and other official government sources, then turns them into a broadcast using the voices of people that communities trust. For some, that'll be DeSantis. For others, it'll be a local sheriff or someone who speaks Spanish. Either way, it's intended to cut down on the manpower needed to get the word out so people can still get accurate information. BEACON is able to recognize which part of the state people live in to send them hyper-local, constant alerts about how they might be affected and what they need to do. It also tells them how to get resources that'll help after the storm. KEVIN GUTHRIE, executive director for the Florida Division of Emergency Management, hopped on the phone to talk about BEACON and other hurricane prep tools with Playbook. Weather forecasters say this year's season is expected to be 'above average,' with anywhere from three to five major hurricanes expected in the Atlantic and Caribbean. BEACON is designed to work even when the power is out and when people don't have cellphone service. It's in several major markets now while it expands statewide, Guthrie said. Floridians will be able to hear its alerts over TV or radio broadcasts, as well as through an app. (Download it for Apple or Android.) Another tool Guthrie is drawing attention to is called Storm Armour, one that's extremely effective in preventing rain from coming in sideways through sliding glass doors and windows. Think of it as working like a sandbag, Guthrie explained. He emphasized that it'll be helpful not just with homes but with condos — where water that enters upper-level units would otherwise seep down to the bottom floors. 'It takes a handful of minutes to install,' Guthrie said. Officials hope that more people will buy the tools so that there's far less flood damage to properties. They retail at $585, but Guthrie said they have the potential to help people avoid tens of thousands of dollars in storm damage. Lastly, Guthrie is doubling down on a key message this hurricane season: Fill up your gas tank when it reaches the halfway mark. The emergency management division started with the campaign, dubbed 'Halfway Full, Halfway There,' last year and wants to double down on it this year so that, if a storm does hit, lines at gas stations won't be as long. Guthrie wants Floridians to get to a place where keeping tanks more full becomes not just best practice, but common practice. 'We're looking for more private-public partnerships to help us get those campaigns out and do some more stuff,' he said. WHERE'S RON? Gov. DeSantis is holding a press conference in Sarasota at 10 a.m. Have a tip, story, suggestion, birthday, anniversary, new job, or any other nugget that Playbook should look at? Get in touch at: kleonard@ Today's Playbook was written with help from Veronica Bianco. ICYMI: The Conversation kicked off with Dr. Oz In the premiere episode of The Conversation, Dasha Burns sat down with Dr. Mehmet Oz — now leading the Centers for Medicare and Medicaid Services — for a candid talk on drug prices, potential Medicaid cuts and why he's getting early morning calls from President Donald Trump. Plus, POLITICO's Jonathan Martin dished on the Ohio governor's race (featuring Elon Musk, Vivek Ramaswamy and former Ohio State football coach Jim Tressel), and Kyle Cheney unpacked Trump's legal battle over 'Liberation Day' tariffs. Watch the full episode on YouTube. And don't miss a moment — subscribe now on Apple Podcasts or Spotify to get new episodes when they drop. ... DATELINE TALLAHASSEE ... BACK TO TALLAHASSEE TOMORROW — 'Florida legislative leaders said late Friday they have forged a budget deal that will guarantee $2.25 billion shifted into tax cuts and reserves while also establishing a path for legislators to avoid a potential shutdown of state government this summer,' reports POLITICO's Gary Fineout. 'The agreement does not include a permanent reduction in the overall sales tax rate … In a memo to senators, Albritton said the plan is for lawmakers to start budget conference meetings Tuesday, with the goal to work over the next two weeks and vote out the budget no later than June 16. … 'The agreement calls for the Legislature to reduce 'recurring revenue' by $2.25 billion including the elimination of sales tax charged on commercial leases and what is being billed as 'permanent sales tax exemptions targeted toward Florida families.' This was not explained further, but Albritton earlier in the year had proposed the permanent elimination of sales taxes on clothing and shoes valued at less than $75.' IN MEMORIAM — 'Former Florida State University President and state House Speaker John Thrasher died early Friday morning, according to a family spokesperson. He was 81,' reports POLITICO's Gary Fineout. 'Thrasher played a pivotal role in Florida's transition from a state long controlled by Democrats to one now dominated by Republicans. … Thrasher served as House speaker in 1999 and 2000, coinciding with then-Gov. Jeb Bush's first years in office and GOP control of both the governor's mansion and Legislature. Thrasher was instrumental in getting legislators to pass several major bills during Bush's first year in office, including his signature A+ education law that first brought private school vouchers in the state and subjected schools to annual grading based on test scores.' TEACHER TRAINING OVERHAUL — 'Legislation signed Friday by Gov. Ron DeSantis calls on the Florida Department of Education to rework key aspects of the teacher certification process by replacing longstanding tests educators needed to pass to earn certification with new measures developed by the state,' reports POLITICO's Andrew Atterbury. 'The new education law also doubles down on Florida's opposition to diversity, equity and inclusion by prohibiting educator training courses from 'distort[ing] significant historical events' or teaching 'identity politics' in language carried over from 'anti-woke' policies passed last year by state Republicans.' — 'DeSantis signs law restricting cellphones in schools,' reports News Service of Florida. PSC HEARINGS CONTINUE — The Public Service Commission this week will wrap up a series of customer service hearings around the state on Florida Power & Light Co.'s $2.5 billion rate hike request. Hearings will be held online Tuesday and Wednesday, followed by hearings Thursday in Pensacola and Friday in Panama City. Last week, 30 environmental and energy justice groups sent a letter to the PSC objecting to FPL's request. — Bruce Ritchie INSIDE THE LATEST COURT ABORTION DECISION — A Florida Appeals Court took an 'unusual legal step' this month when it ruled unconstitutional a law letting minors get abortions without parental consent, reports the Tampa Bay Times' Romy Ellenbogen. The court was initially considering whether to reverse a lower court's denial of a 17-year-old's petition for an abortion but instead decided to rule on the constitutionality of the law that allows minors to file petitions for care in the first place. Florida Attorney General JAMES UTHMEIER and other conservatives heralded the ruling as a win for parental rights and the anti-abortion movement, while abortion access advocates called it a misuse of judicial power. PRICE TRANSPARENCY PUSH — 'Attorney General James Uthmeier issued subpoenas Friday to Florida-based hospitals to ensure they comply with price transparency laws,' reports Cindy Krischer Goodman of the South Florida Sun Sentinel. 'Uthmeier said under Florida law, a hospital's failure to provide price disclosure may constitute an unfair and deceptive trade practice.' — 'A Florida Medicaid patient had a heart attack in South Dakota. He owed the hospital $77,574,' by Arielle Zionts of KFF Health News. PENINSULA AND BEYOND UNDER CONSIDERATION THIS WEEK — The State University's Board of Governors will vote this week on whether to confirm SANTA ONO as University of Florida president, reports Jay Waagmeester of the Florida Phoenix. The proposed contract suggests a compensation package of $3 million a year. MANATEE THREATS — 'An environmental group Friday filed a formal notice that is a step toward suing the federal government over protecting manatees in the Crystal River National Wildlife Refuge,' reports News Service of Florida. 'The Center for Biological Diversity alleged violations of the Endangered Species Act because of understaffing at the refuge, which the notice said serves as a winter habitat for about 20 percent of Florida's manatees drawn by warm-water springs and vegetation.' ...HURRICANE HOLE... DUST WAVE COMING — A massive plume of dust from the Sahara desert is on its way towards Florida and could be visible towards the middle of this week, CBS News' Sarah Lynch Baldwin reports. The National Weather Service said the dust can exacerbate allergies and cause some eye irritation. It's typical for dust to migrate across the Atlantic in the early summer each year. NOAA calls it the Saharan Air Layer, a mass of 'very dry, dusty air' that forms in the desert and floats west over the ocean. The National Hurricane Center's Tropical Analysis and Forecast Branch said the dry air helps suppress storm development. INSURANCE COSTS STILL HIGH — 'The upward rise in costs for homeowner insurance in Florida resumed during the first quarter of 2025, with average premium costs edging higher after dipping slightly in late 2024, new data released by the Florida Office of Insurance Regulation shows,' reports Ron Hurtibise of the South Florida Sun Sentinel. 'The average premium paid by owners of single-family homes in Florida increased by 0.3 percent — climbing from $3,646 to $3,658 — between the fourth quarter of 2024 and the first quarter of 2025, according to a South Florida Sun Sentinel comparison of figures released in the office's quarterly Residential Market Share Report.' MOVING AFTER THE STORM — Some Tampa Bay residents are leaving the hurricane-ridden area for places like Montana, the Midwest and even Australia, the Tampa Bay Times' Michaela Mulligan and Max Chesnes report. People who moved away said massive flooding during Hurricane Helene and widespread power outages during Milton were enough to finally bring them to leave the place that, for some, was home for decades. Others cited affordability, education policy, and more as motivation to leave the state in addition to environmental concerns. CAMPAIGN MODE PRIMARY AHEAD THIS MONTH — 'The Democratic primary to succeed outgoing state Rep. LaVon Bracy Davis will pit her current chief of staff, RaShon Young, against former state Rep. Travaris McCurdy,' reports Steven Lemongello of the Orlando Sentinel. 'The special election for District 40 in western Orange County, a heavily Democratic seat which includes parts of Orlando and Ocoee, is the latest domino effect following the death of state Sen. Geraldine Thompson in February.' — 'August Mangeney launches bid to flip HD 93 back to blue, promises 'people first' agenda,' Florida Politics' Jesse Scheckner reports. — 'Upton Fisher to file to succeed Michele Rayner in HD 62,' by Jacob Ogles of Florida Politics. TRUMPLANDIA AND THE SWAMP SCOTUS DECISION ON IMMIGRATION — 'The Supreme Court has given the Trump administration the go-ahead to begin deporting about a half-million immigrants from Cuba, Haiti, Nicaragua and Venezuela who entered the U.S. legally under 'humanitarian parole' programs implemented during the Biden administration,' reports POLITICO's Josh Gerstein. NEW NASA NOM AHEAD — 'The White House [withdrew] the nomination of Jared Isaacman to be the administrator of the National Aeronautics and Space Administration,' reports POLITICO's Ben Johansen. 'The sudden move [came] days before the Senate was slated to vote on his nomination to lead NASA.' WINTER WHITE HOUSE — 'The man who has led President Donald Trump's Mar-a-Lago Club for three decades is retiring,' reports Kristina Webb of the Palm Beach Daily News. 'Bernd Lembcke, Mar-a-Lago's executive vice president and managing director, announced his retirement in a letter to members dated May 30 and provided to Palm Beach Daily News by a club member.' ODDS, ENDS AND FLORIDA MEN BIRTHDAYS: Former state Rep. Mike Hill … Political analyst and consultant Chris Ingram.
Yahoo
12-05-2025
- Business
- Yahoo
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2025 and provided a corporate update. 'During the first quarter of 2025 we made great progress advancing briquilimab toward important data readouts later this year from all three of our clinical programs in mast cell diseases,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'Updated data from the BEACON study in CSU presented at the AAAAI annual meeting continued to demonstrate the potential of briquilimab to deliver differentiated onset of action, depth of response, and tolerability. We look forward to our mid-year data update in the first half of Q3 2025, which will include additional CSU patients treated in the BEACON study and in the open-label extension study. These data will inform final dose selection for our planned Phase 2b study, expected to commence in the fourth quarter of 2025. We also remain on track to present additional data from the SPOTLIGHT study in CIndU in the second quarter as well as initial data from the ETESIAN study in asthma in the second half of 2025.' Highlights for First Quarter 2025 and Recent Weeks Continued to enroll patients in the BEACON Phase 1b/2a study of subcutaneous briquilimab in CSU. Jasper plans to report data from additional patients enrolled in the BEACON study, as well as from CSU patients enrolled in the open-label extension (OLE) study, in the first half of Q3 2025. Completed enrollment in the third and final cohort (180mg) of the SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in cold urticaria (ColdU) or symptomatic dermographism (SD), the two most prevalent sub types of CIndU. Jasper plans to report data from additional patients enrolled in the study at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in June 2025. Presented updated data from the BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU at the annual meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American Academy of Dermatology (AAD). The update presented was based on a data-cut date of January 31, 2025, and includes approximately one month of additional dosing and follow-up from the 49 participants featured in Jasper's previous data disclosure in January 2025. Briquilimab continued to be well tolerated and demonstrate a favorable safety profile in the study, with no additional adverse events (AEs) potentially related to KIT blockade observed. Data collected in the study to-date support advancing briquilimab into a registrational program in CSU, beginning with a planned Phase 2b operationally-adaptive study expected to commence in the second half of 2025. Final dose selection for the Phase 2b study will be further informed by additional clinical data from patients administered doses of 180mg and higher, expected to be reported mid-year 2025. Open-label Extension Study – Study commenced in CSU that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of their initial follow-up period. The ETESIAN Phase 1b/2a allergen challenge study evaluating a single administration of subcutaneous briquilimab in allergic asthma continues to enroll patients. Jasper expects to report initial data from ETESIAN in the second half of 2025. First Quarter Fiscal 2025 Financial Results Cash and cash equivalents as of March 31, 2025, totaled $48.8 million. Research and development expenses for the three months ended March 31, 2025, was $16.2 million. General and administrative expenses for the three months ended March 31, 2025, was $5.6 million. Jasper reported a net loss of $21.2 million, or basic and diluted net loss per share attributable to common stockholders of $1.41, for the three months ended March 31, 2025. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma and its potential to deliver differentiated onset of action, depth of response and tolerability; Jasper's expected timing for presenting study results for additional CSU patients treated in the BEACON study and in the open-label extension study; its expected timing for presenting additional data from the SPOTLIGHT study and initial data from the ETESIAN study; and its expected timing for commencing its planned Phase 2b operationally adaptive study. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts:Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@ Joyce Allaire (investors)LifeSci Advisors617-435-6602jallaire@ Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@ ---tables to follow---JASPER THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, 2025 2024 Operating expenses Research and development(1) $ 16,157 $ 10,298 General and administrative(1) 5,645 4,774 Total operating expenses 21,802 15,072 Loss from operations (21,802 ) (15,072 ) Interest income 624 1,386 Other expense, net (63 ) (42 ) Total other income, net 561 1,344 Net loss and comprehensive loss $ (21,241 ) $ (13,728 ) Net loss per share attributable to common stockholders, basic and diluted $ (1.41 ) $ (1.03 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 15,022,122 13,334,900 (1) Amounts include non-cash stock based compensation expense as follows (in thousands): Three Months Ended March 31, 2025 2024 Research and development $ 1,240 $ 820 General and administrative 571 349 Total $ 1,811 $ 1,169 JASPER THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) March 31, December 31, Assets 2025 2024 Current assets: Cash and cash equivalents $ 48,799 $ 71,637 Prepaid expenses and other current assets 4,375 4,174 Total current assets 53,174 75,811 Property and equipment, net 1,599 1,875 Operating lease right-of-use assets 1,875 976 Restricted cash 417 417 Other non-current assets 532 820 Total assets $ 57,597 $ 79,899 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,995 $ 4,027 Current portion of operating lease liabilities 1,835 1,089 Accrued expenses and other current liabilities 7,504 10,121 Total current liabilities 12,334 15,237 Non-current portion of operating lease liabilities 755 724 Other non-current liabilities 2,264 2,264 Total liabilities 15,353 18,225 Commitments and contingencies — — Stockholders' equity: Preferred stock — — Common stock 2 2 Additional paid-in capital 304,352 302,541 Accumulated deficit (262,110 ) (240,869 ) Total stockholders' equity 42,244 61,674 Total liabilities and stockholders' equity $ 57,597 $ 79,899
Yahoo
01-03-2025
- Business
- Yahoo
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The BEACON update, based on a data-cut date of January 31, 2025, features approximately one month of additional dosing and follow-up from the 49 participants covered in Jasper's preliminary data disclosure on January 8, 2025. Briquilimab continues to be well tolerated in the study and has continued to demonstrate a favorable safety profile, with no additional adverse events (AEs) potentially related to c-Kit blockade observed. The data collected in the study to-date support advancing briquilimab into a registrational program in CSU, beginning with a planned Phase 2b operationally adaptive study expected to commence in the second half of 2025. Final dose selection for the Phase 2b study will be further informed by additional clinical data from patients treated at doses of 180mg and higher, expected to be reported mid-year 2025. 'I am pleased to present updated data from the BEACON study at AAAAI, which continue to demonstrate that treatment with briquilimab leads to rapid and deep clinical responses in omalizumab-experienced patients with moderate to severe CSU,' said Thomas B. Casale, M.D., Professor of Medicine and Pediatrics, University of South Florida Morsani College of Medicine. 'The safety profile observed is also highly encouraging, with a low frequency of c-Kit related adverse events, which were transient, low-grade, and did not result in any dose delays or discontinuations. The favorable safety data reported in the study are supported by the predictable drug clearance observed, which may allow for restoration of signaling on c-Kit-expressing cells between doses. In addition, the early Tmax observed was consistent with rapid onset of clinical response. Taken together, I believe this data set underscores the potential of briquilimab to serve as a differentiated treatment option for patients with CSU.' 'We remain very excited by the efficacy and safety data generated in the BEACON study,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'We believe that these data demonstrate the potential of briquilimab to differentiate from other therapies, approved and in-development, with regard to onset of action, depth of response, and safety/tolerability. With a substantial number of additional patients being enrolled in the BEACON and SPOTLIGHT studies, as well as patients rolling over from those studies to the Open-Label Extension study, we look forward to reporting data from approximately 70 additional patients treated with briquilimab doses of 180mg or higher around mid-year 2025. These data will inform final dose selection for our planned Phase 2b operationally adaptive study expected to commence later this year.' Details of the presentations are as follows: Abstract Title: Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)Publication Number: L24Session Title: Late Breaking Oral Abstract SessionSession Type: Oral Abstract SessionPresentation Date / Time: Saturday, March 1, 2025; 2:55 p.m. PST Abstract Title: Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)Poster Number: L24Session Title: Late Breaking Poster Session ISession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST Abstract Title: Briquilimab, an Anti-c-Kit Antibody, Induces Durable Depletion of Mast Cells (MCs) Across Multiple Tissues in Mice Expressing Chimeric Human/Mouse CD117 (c-Kit)Poster Number: 540Session Title: Novel Mechanisms of Mast Cells, Basophils and IgESession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell ApoptosisPoster Number: 541Session Title: Novel Mechanisms of Mast Cells, Basophils and IgESession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST Abstract Title: Briquilimab, an Anti-Human CD117 Antibody, Prevents Epicutaneous Oxazolone-Induced Features of Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117Poster Number: 662Session Title: Atopic Dermatitis, Contact Dermatitis, Urticaria, AngioedemaSession Type: Poster SessionSession Date / Time: Sunday, March 2, 2025; 9:45 - 10:45 a.m. PST Abstract Title: Briquilimab, an Anti-Human CD117 Antibody, Treats Low-Calcemic Vitamin D3 Analog MC903-Induced Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117Poster Number: 690Session Title: Atopic Dermatitis, Contact Dermatitis, Urticaria, AngioedemaSession Type: Poster SessionSession Date / Time: Sunday, March 2, 2025; 9:45 - 10:45 a.m. PST About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma, its potential to serve as a differentiated treatment option for patients with CSU, its potential to differentiate from other therapies, approved and in-development, with regard to onset of action, depth of response, and safety/tolerability and its potential allow for restoration of signaling on c-Kit-expressing cells between doses; Jasper's expectations regarding advancing briquilimab into a registrational program in CSU, including the potential commencement of a Phase 2b operationally adaptive study and the expected timing for commencing such trial; the expected timing for reporting additional clinical data from the Phase 1b/2a BEACON study for patients treated at doses of 180mg and higher; and Jasper's poster presentations and oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@ Joyce Allaire (investors)LifeSci Advisors617-435-6602jallaire@ Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@
Yahoo
28-02-2025
- Business
- Yahoo
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced a late-breaking oral presentation of briquilimab data from the Phase 1b/2a BEACON in CSU study at the 2025 AAD Annual Meeting, being held March 7 - 11, 2025, in Orlando, FL. The presentation will consist of data from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the BEACON study. Details of the presentation are as follows: Abstract Title: Briquilimab demonstrates rapid, clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study Abstract Number: S040Session Title: Late Breaking Research: Session 2Session Type: Oral Abstract SessionPresentation Date / Time: Saturday, March 8, 2025; 1 p.m. PST About JasperJasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking StatementsCertain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; and Jasper's late-breaking oral presentation of briquilimab data at the 2025 AAD Annual Meeting. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@ Joyce Allaire (investors)LifeSci Advisors617-435-6602jallaire@ Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@
Yahoo
10-02-2025
- Business
- Yahoo
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced five poster presentations and an oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The oral presentation and one of the poster presentations will include additional follow-up from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the Phase 1b/2a BEACON trial evaluating briquilimab in CSU. Details of the presentations are as follows: Abstract Title: Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)Publication Number: L24Session Title: Late Breaking Oral Abstract SessionSession Type: Oral Abstract SessionPresentation Date / Time: Saturday, March 1, 2025; 2:55 p.m. PST Abstract Title: Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)Poster Number: L24Session Title: Late Breaking Poster Session ISession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST Abstract Title: Briquilimab, an Anti-c-Kit Antibody, Induces Durable Depletion of Mast Cells (MCs) Across Multiple Tissues in Mice Expressing Chimeric Human/Mouse CD117 (c-Kit)Poster Number: 540Session Title: Novel Mechanisms of Mast Cells, Basophils and IgESession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell ApoptosisPoster Number: 541Session Title: Novel Mechanisms of Mast Cells, Basophils and IgESession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST Abstract Title: Briquilimab, an Anti-Human CD117 Antibody, Prevents Epicutaneous Oxazolone-Induced Features of Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117Poster Number: 662Session Title: Atopic Dermatitis, Contact Dermatitis, Urticaria, AngioedemaSession Type: Poster SessionSession Date / Time: Sunday, March 2, 2025; 9:45 - 10:45 a.m. PST Abstract Title: Briquilimab, an Anti-Human CD117 Antibody, Treats Low-Calcemic Vitamin D3 Analog MC903-Induced Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117Poster Number: 690Session Title: Atopic Dermatitis, Contact Dermatitis, Urticaria, AngioedemaSession Type: Poster SessionSession Date / Time: Sunday, March 2, 2025; 9:45 - 10:45 a.m. PST About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; and Jasper's poster presentations and oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@ Joyce Allaire (investors)LifeSci Advisors617-435-6602jallaire@ Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@ in to access your portfolio
